
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva Inc. has demonstrated robust financial growth through its acquisition strategy, with Giapreza experiencing a remarkable 33% sales increase from 2023 to 2024, while Xerava has consistently realized annual sales growth exceeding 20% since its acquisition. The company has reported a total of 65% growth in yearly sales for Giapreza since its acquisition in the third quarter of 2022, highlighting the effectiveness of its integration and management of these assets. Notably, the annualized run rates for Giapreza and Xerava have nearly doubled since Innoviva acquired them, underscoring the company's successful track record in enhancing the performance of its strategic healthcare assets.
Bears say
Innoviva Inc. is facing a challenging financial outlook as the company is projected to experience a year-over-year decline in royalties from key products, with Relvar/Breo expected to decline by 8% and Anoro by 4% annually over the next eight years. Additionally, the anticipated loss of exclusivity for Giapreza in 2034 further exacerbates concerns about future earnings, as it hinges on the patent for its method of use. Compounded by the diminishing efficacy of colistin against multi-drug-resistant strains, these factors indicate a significant risk to Innoviva's long-term revenue stability and growth potential.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares